24
Participants
Start Date
June 30, 2009
Primary Completion Date
May 15, 2017
Study Completion Date
June 30, 2017
Promacta
"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
blood drawing in patients with WAS
blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
blood drawing in healthy controls
blood will be drawn once in healthy children as controls for platelet parameters
Weill Cornell Medical College, New York
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Weill Medical College of Cornell University
OTHER